• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    4/2/24 8:07:01 AM ET
    $ACON
    $ACOR
    $AVTX
    $CMAX
    Medical Specialities
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACON alert in real time by email

    Gainers

    • MSP Recovery (NASDAQ:LIFW) stock increased by 61.9% to $1.08 during Tuesday's pre-market session. The company's market cap stands at $15.9 million.
    • Serina Therapeutics (AMEX:SER) stock moved upwards by 28.33% to $15.18. The company's market cap stands at $152.5 million.
    • CareMax (NASDAQ:CMAX) stock moved upwards by 18.49% to $5.83. The company's market cap stands at $22.1 million.
    • Imunon (NASDAQ:IMNN) stock rose 16.58% to $2.25. The company's market cap stands at $21.1 million. As per the press release, Q4 earnings came out 3 days ago.
    • Mira Pharmaceuticals (NASDAQ:MIRA) shares rose 12.96% to $1.22. The market value of their outstanding shares is at $18.0 million. As per the news, the Q4 earnings report came out yesterday.
    • ThermoGenesis Holdings (NASDAQ:THMO) shares moved upwards by 11.86% to $0.8. The company's market cap stands at $2.5 million.

    Losers

    • Acorda Therapeutics (NASDAQ:ACOR) stock declined by 75.1% to $3.36 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.1 million. As per the news, the Q4 earnings report came out yesterday.
    • Gritstone Bio (NASDAQ:GRTS) stock fell 40.01% to $1.41. The company's market cap stands at $138.2 million.
    • Verve Therapeutics (NASDAQ:VERV) shares fell 34.72% to $8.35. The market value of their outstanding shares is at $698.2 million.
    • Petros Pharma (NASDAQ:PTPI) stock declined by 28.58% to $1.0. The company's market cap stands at $2.2 million. As per the news, the Q4 earnings report came out yesterday.
    • Avalo Therapeutics (NASDAQ:AVTX) shares fell 19.61% to $14.39. The market value of their outstanding shares is at $11.5 million.
    • Aclarion (NASDAQ:ACON) stock declined by 16.27% to $0.34. The company's market cap stands at $2.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON
    $ACOR
    $AVTX
    $CMAX

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    Avalo Therapeutics Inc.
    $AVTX
    9/17/2025$15.00 → $25.00Buy
    H.C. Wainwright
    Avalo Therapeutics Inc.
    $AVTX
    9/5/2025Buy
    TD Cowen
    Avalo Therapeutics Inc.
    $AVTX
    8/15/2025Overweight
    Cantor Fitzgerald
    Avalo Therapeutics Inc.
    $AVTX
    6/2/2025$15.00Buy
    H.C. Wainwright
    Verve Therapeutics Inc.
    $VERV
    4/15/2025Neutral → Overweight
    Cantor Fitzgerald
    Avalo Therapeutics Inc.
    $AVTX
    3/25/2025$36.00Buy
    Stifel
    More analyst ratings

    $ACON
    $ACOR
    $AVTX
    $CMAX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Avalo Therapeutics Inc.

    SCHEDULE 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    2/24/26 4:48:09 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.

    SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

    2/17/26 6:13:19 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.

    SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

    2/17/26 4:21:21 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ACOR
    $AVTX
    $CMAX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Ness Brent bought $62 worth of shares (10 units at $6.20), increasing direct ownership by 1,000% to 11 units (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    12/1/25 5:00:02 PM ET
    $ACON
    Medical Specialities
    Health Care

    Director Braun Donald P bought $29,480 worth of shares (25,000 units at $1.18), increasing direct ownership by 4,188% to 25,597 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    1/28/25 4:18:24 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Almenoff June Sherie bought $12,750 worth of shares (1,000 units at $12.75) (SEC Form 4)

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    11/14/24 5:21:55 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ACOR
    $AVTX
    $CMAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avalo Therapeutics to Participate in Upcoming Investor Conferences

    WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: TD Cowen Annual Healthcare ConferenceFireside Chat March 3, 2026, at 9:50 am ET Leerink Partners Global Healthcare ConferenceFireside ChatMarch 10, 2026, at 4:20 pm ET Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for

    2/24/26 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

    WAYNE, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to two new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 82,000 shares of common stock (the "Options") as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Options were granted on February 13, 2026 and have an exercise price of $14.

    2/18/26 4:05:00 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY

    Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 Study Khursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years at the company Phase 3 Study enrollment remains ahead of schedule and advances the company toward future BLA filing LAWRENCEVILLE, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced a strategic reorganization that will eliminate headcount not essential to the Phase 3 trial and redefine the job descriptions for additional employees to reduce operating expenses while supporting the co

    2/5/26 8:05:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ACOR
    $AVTX
    $CMAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Avalo Therapeutics with a new price target

    Mizuho initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $39.00

    12/18/25 9:07:24 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright reiterated coverage on Avalo Therapeutics with a new price target

    H.C. Wainwright reiterated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $25.00 from $15.00 previously

    9/17/25 11:38:46 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ACOR
    $AVTX
    $CMAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Legal Officer Varki Paul

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    3/2/26 4:24:17 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Strategy Officer Riley Jennifer

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    3/2/26 4:23:32 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Doyle Mittie

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    3/2/26 4:23:06 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ACOR
    $AVTX
    $CMAX
    Leadership Updates

    Live Leadership Updates

    View All

    Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

    Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managementStrengthens Aclarion's commercial execution as the Company expands adoption and payer engagement across the Eastern U.S. BROOMFIELD, Colo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the

    12/2/25 8:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

    Marks Aclarion's first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgeryExperiencing strong commercial traction in UK as first market worldwide with private insurers covering NociscanNociscan reimbursed by three of top four private insurers in UK, giving access to more than 5.2 million covered lives BROOMFIELD, Colo., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announc

    11/5/25 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

    WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. "We are delighted to welcome Taylor and Ashley to Avalo as we enter a transformational period for the Company, including advancing AVTX-009 through the LOTUS Phase 2 trial in hidradenitis suppurativa and preparing for a data readout mid next year," said Dr. Garry Nei

    10/1/25 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ACOR
    $AVTX
    $CMAX
    Financials

    Live finance-specific insights

    View All

    IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update

    R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advanced ovarian cancer Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today reported financial results for the three-month and nine-month periods ended September 30, 2025, and highlighted recent business updates, including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed

    11/13/25 7:45:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025

    LAWRENCEVILLE, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at 11:00 a.m. ET on Thursday, November 13, 2025 to discuss financial results for the third quarter ended September 30, 2025, and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy. To participate in the call, interested parties may dial 833-816-1132 (Toll-Free/North America) or 412-317-0711 (International/Toll) and ask for the IMUNON Third Quarter 2025 Financial Results Call. A live webcast of the

    11/6/25 8:05:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

    LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market following confirmation from the Nasdaq Hearings Panel. As a result, IMUNON common stock will continue uninterrupted trading on The Nasdaq Capital Market. "Having regained compliance with Nasdaq's minimum bid price listing requirement, investors in IMUNON's stock are assured of efficient liquidity as provided by the exchange. Our ongoing confidence in our listing with the Nasdaq coi

    8/28/25 8:05:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ACOR
    $AVTX
    $CMAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    SEC Form SC 13G filed by Verve Therapeutics Inc.

    SC 13G - Verve Therapeutics, Inc. (0001840574) (Subject)

    11/18/24 5:23:52 PM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Avalo Therapeutics Inc.

    SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    11/14/24 6:23:00 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care